About Viridos
                            Viridos develops genomic-driven solutions to address global energy and environmental challenges.                        
                                                    
                                    Headquarters
                                    Viridos, La Jolla
                                
                                                                                                
                                    Founded
                                    2005-01-01
                                
                                                                
                                                                
                                    Industry
                                    Biotechnology, Health Care, Medical, Renewable Energy
                                
                                                                                                
                                    Last Funding Type
                                    Series A
                                
                                                                                                    
                                        Valuation
                                        1
                                    
                                                                                                
                                                                        Total Funding
                                    $202.00 million dollars
                                
                                                                                                
                                    IPO Status
                                    Private
                                
                                                            Financial
                                Viridos is focused on developing genetically modified algae to enhance lipid and biomass productivity. Their research includes creating recombinant algal mutants with modifications in genes encoding WD40 repeat proteins, trehalose biosynthetic enzymes, and protein kinase-like proteins. These modifications result in higher lipid and biomass productivity. Additionally, they explore mutant photosynthetic microorganisms with reduced chlorophyll for increased productivity and Chlorophyte algae with improved productivity through genetic modifications in chloroplastic signal recognition particles.
                            
                            
                                    Funding Rounds
                                    10
                                
                                                                                                
                                    Number of Lead Investors
                                    5
                                
                                                                                                
                                                                        Total Funding Amount 
                                    $202.00 million dollars
                                
                                                                                                
                                    Number of Investors
                                    12